RxDoctor Payments Data

Janet Scholle, MD

Psychiatry · Wpb, FLNPI 1124076302

Payments from drug & device makers

$9,530in general payments, 2019–2025

Across 128 payments — averaging $74.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$468
  • Otsuka America Pharmaceutical, Inc.$417
  • Sunovion Pharmaceuticals Inc.$337
  • Neurocrine Biosciences, Inc.$328
  • Takeda Pharmaceuticals U.S.A., Inc.$277
  • plus $939 from 11 others

What the payments were for

  • Speaking & faculty fees$6,16065%
  • Food & beverage$3,19033%
  • Education$1802%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,530 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$50,442
Medicare patients
37
Services billed
404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl23$32,317
CaplytaLumateperone Tosylate14$27,007
RexultiBrexpiprazole11$16,692
TrintellixVortioxetine Hydrobromide16$14,607
SeroquelQuetiapine Fumarate13$12,355
ValiumDiazepam12$11,632
VyvanseLisdexamfetamine Dimesylate14$6,052
Quetiapine Fumarate61$2,463
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine90$2,029
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine34$1,835
Bupropion XlBupropion Hcl97$1,697
Lamotrigine80$1,244
Methylphenidate ErMethylphenidate Hcl15$1,238
Methylphenidate Hcl38$1,197
Trazodone Hcl69$1,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$6,763$32,31723 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$468$27,00714 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$277$20,65930 claims
Otsuka America Pharmaceutical, Inc.Rexulti$417$16,69211 claims
Almatica Pharma LLCSertraline Hcl$90$41338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Wpb

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →